Oppenheimer & Co. Inc. Has $272,000 Holdings in Solventum Co. (NYSE:SOLV)

Oppenheimer & Co. Inc. lessened its holdings in shares of Solventum Co. (NYSE:SOLV) by 9.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,112 shares of the company’s stock after selling 412 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Solventum were worth $272,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Trian Fund Management L.P. raised its stake in Solventum by 32.9% during the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after buying an additional 1,765,676 shares during the period. State Street Corp raised its stake in Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after buying an additional 185,938 shares during the period. Geode Capital Management LLC raised its stake in Solventum by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock worth $232,608,000 after buying an additional 128,317 shares during the period. Hotchkis & Wiley Capital Management LLC acquired a new stake in Solventum during the 3rd quarter worth $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Solventum by 0.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock worth $73,469,000 after buying an additional 3,745 shares during the period.

Solventum Price Performance

NYSE:SOLV opened at $77.96 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The stock’s 50-day simple moving average is $73.65 and its 200 day simple moving average is $70.63. The company has a market cap of $13.47 billion and a P/E ratio of 28.35. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92.

Wall Street Analyst Weigh In

SOLV has been the topic of several recent research reports. Wells Fargo & Company lifted their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Bank of America boosted their price target on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. Mizuho boosted their price target on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. Piper Sandler boosted their price target on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Finally, The Goldman Sachs Group boosted their price target on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.